Senior ML Research Scientist
Rad AI- Full Time
- Senior (5 to 8 years)
Employment Type: Full-Time Location Type: Remote Salary: [Not Specified]
Iambic Therapeutics is seeking a Machine Learning Scientist II or Senior to enhance its Enchant platform by integrating clinically relevant imaging. The successful candidate will be responsible for designing and building models that leverage medical images and multimodal biomedical data to advance drug discovery and clinical decision-making. This is a remote position, with a preference for candidates located in Bristol.
Iambic is a clinical-stage life-science and technology company dedicated to developing novel medicines through its AI-driven discovery and development platform. Founded in 2020 and based in San Diego, Iambic has assembled a world-class team comprising pioneering AI experts and seasoned drug hunters. The Iambic platform has a proven track record of delivering new drug candidates to human clinical trials with exceptional speed across various target classes and mechanisms of action. Iambic is actively advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and through partnerships, to address urgent unmet patient needs. More information about the Iambic team, platform, pipeline, and partnerships can be found at iambic.ai.
Iambic's mission is to deliver better medicines through innovations in AI-based discovery technologies. The company's culture and work are significantly enriched by the diversity of its people, including their backgrounds, cultures, national origins, religions, sexual orientations, and life experiences. Iambic is committed to fostering an inclusive environment where a diverse group of talented individuals collaborate to discover therapeutics and create cutting-edge technologies.
Iambic Therapeutics offers a competitive compensation package, pension contributions, and flexible holiday allowances. The UK office provides a modern and collaborative work environment located in the heart of Bristol.
[Not Specified]
Develops therapies for CNS disorders
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.